Share This Page
Drug Sales Trends for ENBREL SRCLK
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for ENBREL SRCLK
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| ENBREL SRCLK | ⤷ Try for Free | ⤷ Try for Free | 2021 |
| ENBREL SRCLK | ⤷ Try for Free | ⤷ Try for Free | 2020 |
| ENBREL SRCLK | ⤷ Try for Free | ⤷ Try for Free | 2019 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Market Analysis and Sales Projections for Enbrel
Overview of Enbrel
Enbrel, developed by Immunex and now owned by Amgen, is a biologic drug used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and others. It is a dimeric fusion protein that inhibits the binding of tumor necrosis factor (TNF) alpha and beta to cell surface receptors, rendering TNF biologically inactive[4].
Market Size and Growth Projections
The global Enbrel market has been valued at USD 15.5 billion in 2022 and is projected to grow to USD 23.2 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 3.7% from 2023 to 2032[1].
Key Drivers of Market Growth
Escalating Autoimmune Disorder Incidence
The increasing prevalence of autoimmune diseases such as rheumatoid arthritis and psoriasis is a significant driver for the Enbrel market. These chronic conditions often require long-term biological treatments, thereby increasing the demand for Enbrel[1].
Biotechnology Progression
Advancements in biotechnology, including improved drug delivery systems and targeted therapies, are expected to enhance the efficacy and user-friendliness of Enbrel. This could attract a broader patient demographic and healthcare providers to the market[1].
Personalized Medicine
The trend towards personalized medicine allows for tailored treatment plans using Enbrel, optimizing patient outcomes and reducing adverse effects. This approach is likely to attract more patients and healthcare providers[1].
Digital Health and Telemedicine
The integration of telemedicine and digital health tools has expanded patient access to Enbrel, enabling remote monitoring, improved patient engagement, and better adherence to treatment regimens[1].
Competitive Landscape
Biosimilar Competition
The emergence of biosimilar versions of Enbrel has introduced competition, potentially lowering treatment costs and increasing accessibility for patients. However, analysts predict that biosimilars will not significantly halt the revenue growth of Enbrel in the near term. Biosimilars are expected to erode up to 30% of Enbrel's sales in their first year but will not completely replace the branded drug[2].
Market Saturation and Emerging Therapies
In some regions, the Enbrel market may be saturated, leaving limited room for further expansion. Additionally, ongoing research and development may lead to the discovery of new and more effective treatments for autoimmune diseases, potentially diverting market share away from Enbrel[1].
Regional Market Analysis
North America and Europe
These regions currently dominate the Enbrel market due to the presence of major pharmaceutical companies and a high prevalence of autoimmune diseases. North America, in particular, held a significant share of the etanercept market in 2021, driven by the presence of major pharma conglomerates[3].
Asia Pacific
The Asia Pacific region is expected to be a profitable venture for Enbrel marketers between 2022 and 2032, driven by growing healthcare needs and increasing access to biologic treatments[1][3].
Sales Projections
Historical Sales
From 1998 to 2018, Enbrel generated $87.97 billion in sales. It is projected to rake in $31.66 billion from 2019 to 2024[5].
Future Projections
By 2032, the global Enbrel market is expected to reach USD 23.2 billion. This growth is supported by the drug's continued approvals for various indications and the expanding patient base in emerging markets[1].
Challenges and Threats
Economic Factors and Healthcare Policies
Economic downturns and changes in healthcare reimbursement policies can affect patients' ability to afford Enbrel, leading to decreased demand. Efforts to control healthcare costs, including drug pricing regulations, can also impact the market[1].
Adverse Events and Safety Concerns
Any safety issues or adverse events associated with Enbrel can significantly impact its market reputation and demand. Continuous monitoring and management of these risks are crucial for maintaining market share[1].
Global Health Crises
Unexpected global health crises, such as pandemics, can disrupt the pharmaceutical supply chain, leading to shortages and impacting the availability of Enbrel[1].
Key Takeaways
- The global Enbrel market is projected to grow from USD 15.5 billion in 2022 to USD 23.2 billion by 2032, with a CAGR of 3.7%.
- The market is driven by the increasing prevalence of autoimmune diseases and advancements in biotechnology.
- Biosimilar competition is expected but will not halt Enbrel's revenue growth significantly in the near term.
- Regional expansion, particularly in the Asia Pacific, is a key growth strategy.
- Economic factors, healthcare policies, and safety concerns are significant challenges that need to be addressed.
FAQs
Q: What is the current market size of Enbrel and its projected growth? A: The global Enbrel market was valued at USD 15.5 billion in 2022 and is projected to reach USD 23.2 billion by 2032, growing at a CAGR of 3.7% from 2023 to 2032[1].
Q: What are the main drivers of the Enbrel market? A: The main drivers include the increasing prevalence of autoimmune diseases, advancements in biotechnology, personalized medicine, and the integration of digital health and telemedicine[1].
Q: How will biosimilars impact the Enbrel market? A: Biosimilars are expected to introduce competition, potentially lowering treatment costs and increasing accessibility, but they will not significantly halt Enbrel's revenue growth in the near term[2].
Q: Which regions are expected to drive the growth of the Enbrel market? A: North America and Europe currently dominate the market, but the Asia Pacific region is expected to be a profitable venture for Enbrel marketers in the coming years[1][3].
Q: What are some of the challenges facing the Enbrel market? A: Challenges include economic factors, changes in healthcare reimbursement policies, adverse events and safety concerns, and global health crises[1].
Sources
- Custom Market Insights: Global Enbrel Market Size, Trends, Share, Forecast 2032.
- FiercePharma: Biosimilars won't stop Enbrel, Humira from growing through 2022.
- GlobeNewswire: At CAGR of 3.3% Global Etanercept Market Size & Share | 2022 - 2028.
- GlobalData: The Global Drug sales of Enbrel (2020 - 2026, USD Millions).
- BioSpace: Report: Projected Sales of 10 Top-Selling Drugs Through 2024.
More… ↓
